Ignite Creation Date:
2024-05-05 @ 11:30 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00063206
Status:
COMPLETED
Last Update Posted:
2009-08-19
First Post:
2003-06-23
Brief Title:
Study Evaluating DVS-233 in Adult Outpatients With Major Depressive Disorder
Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Organization:
Wyeth is now a wholly owned subsidiary of Pfizer
Study Overview
Official Title:
A Multicenter Randomized Double-blind Placebo-Controlled Parallel-Group Efficacy and Safety Study of a Flexible Dose of DVS-233 SR in Adult Outpatients With Major Depressive Disorder
Status:
COMPLETED
Status Verified Date:
2009-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Primary To compare the antidepressant efficacy and safety of subjects receiving DVS-233 SR versus subjects receiving placebo
Secondary To assess the response of subjects receiving DVS-233 SR for the clinical global evaluation functionality general well-being pain and remission Hamilton Psychiatric Rating Scale for Depression 17-item HAM-Dsub17sub 7 versus those subjects receiving placebo
Secondary To assess the response of subjects receiving DVS-233 SR for the clinical global evaluation functionality general well-being pain and remission Hamilton Psychiatric Rating Scale for Depression 17-item HAM-Dsub17sub 7 versus those subjects receiving placebo
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None